Patents by Inventor Robert A. Fridell

Robert A. Fridell has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Inhibitors of human immunodeficiency virus replication
    Patent number: 10221129
    Abstract: Compounds of Formula I, including pharmaceutically acceptable salts thereof, and compositions and methods for treating human immunodeficiency virus (HIV) infection are set forth:
    Type: Grant
    Filed: April 22, 2016
    Date of Patent: March 5, 2019
    Assignee: VIIV HEALTHCARE UK (NO.5) LIMITED
    Inventors: John A. Bender, Robert G. Gentles, Annapurna Pendri, Alan Xiangdong Wang, Nicholas A. Meanwell, Brett R. Beno, Robert A. Fridell, Makonen Belema, Van N. Nguyen, Zhong Yang, Gan Wang, Selvakumar Kumaravel, Srinivasan Thangathirupathy, Rajesh Onkardas Bora, Shilpa Maheshwarappa Holehatti, Mallikarjuna Rao Mettu, Manoranjan Panda
  • Inhibitors of human immunodeficiency virus replication
    Patent number: 10035760
    Abstract: Compounds of Formula I with activity against HIV, including pharmaceutical compositions and methods for using these compounds in treating human immunodeficiency virus (HIV) infection, are set forth:
    Type: Grant
    Filed: October 23, 2014
    Date of Patent: July 31, 2018
    Assignee: ViiV HEALTHCARE UK (NO. 5) LIMITED
    Inventors: Annapurna Pendri, Guo Li, John A. Bender, Zhong Yang, Alan Xiangdong Wang, Brett R. Beno, Robert A. Fridell, Makonen Belema, Nicholas A. Meanwell, Robert G. Gentles
  • INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION
    Publication number: 20180086697
    Abstract: Compounds of Formula I, including pharmaceutically acceptable salts thereof, and compositions and methods for treating human immunodeficiency virus (HIV) infection are set forth:
    Type: Application
    Filed: April 22, 2016
    Publication date: March 29, 2018
    Inventors: John A. BENDER, Robert G. GENTLES, Annapurna PENDRI, Alan Xiangdong WANG, Nicholas A. MEANWELL, Brett R. BENO, Robert A. FRIDELL, Makonen BELEMA, Van N. NGUYEN, Zhong YANG, Gan WANG, Selvakumar KUMARAVEL, Srinivasan THANGATHIRUPATHY, Rajesh Onkardas BORA, Shilpa Maheshwarappa HOLEHATTI, Mallikarjuna Rao METTU, Manoranjan PANDA
  • INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION
    Publication number: 20180072997
    Abstract: Compounds of Formulas I-VI, including pharmaceutically acceptable salts thereof, and compositions and methods for treating human immunodeficiency virus (HIV) infection are set forth.
    Type: Application
    Filed: April 22, 2016
    Publication date: March 15, 2018
    Inventors: John A. BENDER, Omar D. LOPEZ, Van N. NGUYEN, Zhong YANG, Alan Xiangdong WANG, Gan WANG, Nicholas A. MEANWELL, Brett R. BENO, Robert A. FRIDELL, Makonen BELEMA, Srinivasan THANGATHIRUPATHY
  • INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION
    Publication number: 20160257645
    Abstract: Compounds of Formula I with activity against HIV, including pharmaceutical compositions and methods for using these compounds in treating human immunodeficiency virus (HIV) infection, are set forth: Formula: (I)
    Type: Application
    Filed: October 23, 2014
    Publication date: September 8, 2016
    Inventors: Annapurna Pendri, Guo Li, John A. Bender, Zhong Yang, Alan Xiangdong Wang, Brett R. Beno, Robert A. Fridell, Makonen Belema, Nicholas A. Meanwell, Robert G. Gentles
  • HEPATITIS C VIRUS INHIBITORS
    Publication number: 20160199355
    Abstract: The present disclosure is generally directed to antiviral compounds, and more specifically directed to combinations of compounds which can inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV), compositions comprising such combinations, and methods for inhibiting the function of the NS5A protein.
    Type: Application
    Filed: March 11, 2016
    Publication date: July 14, 2016
    Inventors: PIYASENA HEWAWASAM, JOHN F. KADOW, OMAR D. LOPEZ, NICHOLAS A. MEANWELL, YONG TU, ALAN XIANGDONG WANG, NINGNING XU, SAMAYAMUNTHULA VENKATA SATYA ARUN KUMAR GUPTA, POTHUKANURI SRINIVASU, INDASI GOPI KUMAR, PONUGUPATI SURESH KUMAR, MAKONEN BELEMA, ROBERT A. FRIDELL, MIN GAO, JULIE A. LEMM, DONALD R. O'BOYLE, II, JIN-HUA SUN, CHUNFU WANG, YING-KAI WANG
  • Hepatitis C virus inhibitors
    Patent number: 9326973
    Abstract: The present disclosure is generally directed to antiviral compounds, and more specifically directed to combinations of compounds which can inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV), compositions comprising such combinations, and methods for inhibiting the function of the NS5A protein.
    Type: Grant
    Filed: January 7, 2013
    Date of Patent: May 3, 2016
    Assignee: Bristol-Myers Squibb Company
    Inventors: Piyasena Hewawasam, John F. Kadow, Omar D. Lopez, Nicholas A. Meanwell, Yong Tu, Alan Xiangdong Wang, Ningning Xu, Samayamunthula Venkata Satya Arun Kumar Gupta, Pothukanuri Srinivasu, Indasi Gopi Kumar, Ponugupati Suresh Kumar, Makonen Belema, Robert A. Fridell, Min Gao, Julie A. Lemm, Donald R. O'Boyle, II, Jin-Hua Sun, Chunfu Wang, Ying-Kai Wang
  • Viral envelope mediated fusion assay
    Publication number: 20040106104
    Abstract: This invention provides a method of screening a sample for susceptibility to a viral entry inhibitor. The invention further provides a method for monitoring a patient for sensitivity to a viral entry inhibitor and a method of determining an inhibitory concentration of a viral entry inhibitor to inhibit virus infection in a patient. A method of screening for viral entry inhibitors is also provided.
    Type: Application
    Filed: June 11, 2003
    Publication date: June 3, 2004
    Inventors: Pin-Fang Lin, Carol Deminie, Robert A. Fridell, Brett Robinson, Ronald E. Rose